DCTH DELCATH SYSTEMS, INC.

Nasdaq delcath.com


$ 11.34 $ -0.06 (-0.53 %)    

Tuesday, 21-Oct-2025 11:15:06 EDT
QQQ $ 611.17 $ -0.34 (-0.05 %)
DIA $ 471.16 $ 4.04 (0.86 %)
SPY $ 672.35 $ 0.86 (0.13 %)
TLT $ 92.01 $ 0.02 (0.02 %)
GLD $ 380.83 $ -5.86 (-1.49 %)
$ 11.42
$ 11.41
$ 11.32 x 83
$ 11.35 x 190
$ 11.09 - $ 11.50
$ 8.87 - $ 18.23
3,625,510
na
399.49M
$ 1.14
$ 178.98
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-22-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 07-17-2019 03-31-2019 10-Q
27 06-14-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-29-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-18-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-delcath-systems-lowers-price-target-to-30

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri...

 reported-saturday-delcath-systems-posts-205m-q3-revenue-08m-net-income-and-87-gross-margin-sees-2025-revenue-outlook-of-83m85m-with-150-treatment-volume-growth-forecast

Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEP...

 delcath-systems-announces-the-acceptance-of-an-oral-presentation-on-results-from-the-investigator-initiated-chopin-randomized-phase-2-trial-at-the-2025-european-society-for-medical-oncology-annual-congress

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-31

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-q2-eps-007-beats-002-estimate-sales-2416m-beat-2283m-estimate

Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02...

 stephens--co-reiterates-overweight-on-delcath-systems-maintains-25-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overweight and maintains $25 pri...

 hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-29

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

 delcath-systems-sees-2025-chemosat-and-hepzato-kit-revenue-climbing-to-94m98m-in-2025-up-over-150-yoy-sees-8385-gross-margins

2025 Full Year Total Revenue Guidance of $94 to $98 millionDelcath Announces Plan to Enter into National Medicaid Drug Rebate A...

 delcath-systems-receives-fda-clearance-of-ind-application-for-phase-2-clinical-trial-of-hepzato-in-liver-dominant-metastatic-breast-cancer

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION